Tower Research Capital LLC TRC Cuts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Tower Research Capital LLC TRC trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 45.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,521 shares of the medical research company's stock after selling 3,709 shares during the quarter. Tower Research Capital LLC TRC's holdings in Charles River Laboratories International were worth $835,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Virtu Financial LLC bought a new position in shares of Charles River Laboratories International during the 3rd quarter worth approximately $601,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at $59,000. Tidal Investments LLC raised its stake in shares of Charles River Laboratories International by 37.8% during the 3rd quarter. Tidal Investments LLC now owns 8,452 shares of the medical research company's stock valued at $1,665,000 after buying an additional 2,319 shares during the last quarter. Lord Abbett & CO. LLC lifted its holdings in Charles River Laboratories International by 5.8% in the third quarter. Lord Abbett & CO. LLC now owns 108,715 shares of the medical research company's stock valued at $21,413,000 after acquiring an additional 5,959 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in Charles River Laboratories International by 3.6% during the third quarter. Principal Financial Group Inc. now owns 60,501 shares of the medical research company's stock worth $11,917,000 after buying an additional 2,126 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Analyst Ratings Changes

CRL has been the topic of several research analyst reports. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and raised their price objective for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. Mizuho lowered their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Barclays reduced their target price on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. UBS Group reaffirmed a "neutral" rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective on the stock in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $182.00.

Insider Activity

In related news, CEO James C. Foster acquired 6,075 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Up 2.0 %

Shares of CRL stock traded up $2.27 on Tuesday, hitting $117.35. The stock had a trading volume of 1,347,314 shares, compared to its average volume of 925,584. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The firm has a market capitalization of $5.76 billion, a P/E ratio of 782.33, a P/E/G ratio of 4.54 and a beta of 1.45. The company's 50 day moving average price is $145.74 and its 200-day moving average price is $170.44. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International's revenue was down 1.1% compared to the same quarter last year. During the same period last year, the business posted $2.46 earnings per share. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).